Head to Head Review: Kazia Therapeutics (NASDAQ:KZIA) and Organogenesis (NASDAQ:ORGO)

Organogenesis (NASDAQ:ORGO) and Kazia Therapeutics (NASDAQ:KZIA) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, risk, dividends, analyst recommendations, earnings and profitability.

Risk and Volatility

Organogenesis has a beta of 1.65, suggesting that its share price is 65% more volatile than the S&P 500. Comparatively, Kazia Therapeutics has a beta of 2.15, suggesting that its share price is 115% more volatile than the S&P 500.

Profitability

This table compares Organogenesis and Kazia Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Organogenesis	1.34%	2.11%	1.27%
Kazia Therapeutics	N/A	N/A	N/A

Analyst Recommendations

This is a breakdown of current ratings and price targets for Organogenesis and Kazia Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Organogenesis	0	1	3	0	2.75
Kazia Therapeutics	0	0	1	0	3.00

Organogenesis currently has a consensus price target of $4.88, suggesting a potential upside of 53.79%. Kazia Therapeutics has a consensus price target of $2.00, suggesting a potential upside of 426.32%. Given Kazia Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Kazia Therapeutics is more favorable than Organogenesis.

Institutional & Insider Ownership

49.6% of Organogenesis shares are held by institutional investors. Comparatively, 30.9% of Kazia Therapeutics shares are held by institutional investors. 34.0% of Organogenesis shares are held by company insiders. Comparatively, 1.0% of Kazia Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Earnings and Valuation

This table compares Organogenesis and Kazia Therapeutics’ gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Organogenesis	$433.14 million	0.97	$4.95 million	$0.04	79.27
Kazia Therapeutics	$20,000.00	310.46	-$13.78 million	N/A	N/A

Organogenesis has higher revenue and earnings than Kazia Therapeutics.

Summary

Organogenesis beats Kazia Therapeutics on 8 of the 12 factors compared between the two stocks.

About Organogenesis

Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage. Its products also include FortiShield, a biosynthetic wound matrix for use as a temporary protective covering; PuraPly MZ, a micronized particulate version of PuraPly for the management of open wounds in the surgical setting; and CYGNUS Dual, a dehydrated placental tissue preserved to retain the ECM scaffold. The company's pipeline products include ReNu, a cryopreserved suspension used to support healing of soft tissues; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; and TransCyte, a bioengineered tissue for the treatment of partial thickness burns. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician office through direct sales representives and independent agencies. Organogenesis Holdings Inc. was founded in 1985 and is headquartered in Canton, Massachusetts.

About Kazia Therapeutics

Kazia Therapeutics Limited operates as a biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma, diffuse intrinsic pontine glioma/advanced solid tumors, atypical teratoid rhabdoid tumor, brain metastases, triple negative breast cancer, and primary central nervous system lymphoma. It is also developing EVT801, a small molecule targeted therapeutic vascular endothelial growth factor receptor 3 inhibitor. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. The company was incorporated in 1994 and is based in Sydney, Australia.